Role of lymphadenectomy in the management of grossly apparent advanced stage epithelial ovarian cancer

被引:66
|
作者
Aletti, Giovanni D. [1 ]
Dowdy, Sean [1 ]
Podratz, Karl C. [1 ]
Cliby, William A. [1 ]
机构
[1] Mayo Clin & Mayo Fdn, Dept Obstet & Gynecol, Rochester, MN 55905 USA
关键词
lymphadenectomy; cytoreduction; node metastasis; ovarian cancer;
D O I
10.1016/j.ajog.2006.06.068
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective: The purpose of this study was to determine the factors that are related to the performance of lymph node assessment and its impact on prognosis in ovarian cancer. Study design: This was a retrospective analysis of stage IIIC/IV epithelial ovarian cancer in patients who had undergone primary surgery between 1994 and 1998. Simple statistics and univariate and multivariable analysis were performed. Results: Two hundred nineteen patients met the inclusion criteria; lymph node assessment was performed for 93 of these patients (41%). Sixty-one patients (65.5%) underwent complete pelvic and para-aortic lymphadenectomy, and 32 patients (34.5%) underwent a more limited lymph node sampling. In patients with residual disease > 1 cm, lymph node assessment was an independent predictor of outcome. In this same subgroup, lymphadenectomy appeared to be superior to lymph node sampling (5-year overall survival, 50% (lymphadenectomy) vs 33% (lymph node sampling) vs 29% (no lymph node assessment); P =.01). Considering survival of the subgroup who underwent lymph node assessment, we observed a significantly worse outcome for those with lymphatic involvement (5-year overall survival, 31.5% [positive for nodal metastases] vs 54% [negative for nodal metastases]; P =.003). Although multiple factors were correlated with the decision to perform lymph node assessment in univariate analysis, only the surgeon (P <.001), low residual disease (P =.004), American Society of Anesthesiology I or 2 (P =.004), and the absence of carcinomatosis (P =.0002) were independent factors in the multivariable analysis. Further, if lymph node assessment was performed, the decision to do lymphadenectomy versus lymph node sampling was associated independently with the surgeon (P <.001), low residual disease (P <.001), and patient age of < 65 years (P <.001). Conclusion: Removal of obviously involved lymph nodes in patients with residual disease near 1 cm and lymphadenectomy for patients with complete or near complete resection of abdominal disease appears to be justified. A lack of standard recommendation in advanced ovarian cancer results in wide variations that are based on individual preference in addition to logical factors. (c) 2006 Mosby, Inc. All rights reserved.
引用
收藏
页码:1862 / 1868
页数:7
相关论文
共 50 条
  • [31] Role of lymphadenectomy in ovarian cancer
    Panici, PB
    Angioli, R
    [J]. BEST PRACTICE & RESEARCH IN CLINICAL OBSTETRICS & GYNAECOLOGY, 2002, 16 (04): : 529 - +
  • [32] No benefit of lymphadenectomy for advanced ovarian cancer
    Gourd, Elizabeth
    [J]. LANCET ONCOLOGY, 2019, 20 (04): : E195 - E195
  • [33] THE ROLE OF SYSTEMATIC PELVIC AND PARA-AORTIC LYMPHADENECTOMY FOR STAGE II ∼ IV EPITHELIAL OVARIAN CANCER PATIENTS
    Sueoka, K.
    Okada-Hayashi, M.
    Nakashima, K.
    Kajimura, T.
    Taketani, T.
    Sugino, N.
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2018, 28 : 842 - 842
  • [34] Role of lymphadenectomy for apparent early-stage low-grade serous ovarian carcinoma
    Nasioudis, Dimitrios
    George, Erin
    Latif, Nawar
    Ko, Emily
    Haggerty, Ashley
    Cory, Lori
    Giuntoli, Robert
    Kim, Sarah
    Morgan, Mark
    Simpkins, Fiona
    [J]. GYNECOLOGIC ONCOLOGY, 2022, 166 : S259 - S260
  • [35] The. role of extensive lymphadenectomy in stage I ovarian cancer.
    Munro, E. G.
    Lee, N. Karnik
    Cheung, M. K.
    Osann, K.
    Husain, A.
    Teng, N. N.
    Kapp, D. S.
    Berek, J. S.
    Chan, J. K.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 272S - 272S
  • [36] Lymph node involvement and the role of lymphadenectomy in patients with advanced ovarian cancer
    Slavchev, Stanislav
    Yordanov, Angel
    Nanev, Vasil
    Ivanova, Denislava
    Ivanov, Momchil
    Strashilov, Strahil
    [J]. AUSTRALASIAN MEDICAL JOURNAL, 2019, 12 (07): : 200 - 205
  • [37] Management of nodal disease in advanced-stage ovarian cancer: porta hepatis, celiac, pelvic and paraaortic lymphadenectomy
    Taskiran, Cagatay
    Giray, Burak
    Vatansever, Dogan
    Bilge, Orhan
    [J]. EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2022, 43 (03) : 36 - 45
  • [38] FULL SYSTEMATIC LYMPHADENECTOMY FOR APPARENT EARLY STAGE OVARIAN CANCER: IMPACT ON SPECIFIC LYMPHATIC MORBIDITY
    Ervas, E.
    Longo, M.
    Lembo, A.
    Artuso, V.
    Di Siena, A.
    Ghezzi, F.
    Casarin, J.
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2021, 31 : A116 - A116
  • [39] The Role of Surgery in the Management of Epithelial Ovarian Cancer
    Ramirez, Ingrid
    Chon, Hye Sook
    Apte, Sachin M.
    [J]. CANCER CONTROL, 2011, 18 (01) : 22 - 30
  • [40] Role of chemotherapy in the management of epithelial ovarian cancer
    Reed, NS
    Sadozye, AH
    [J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2005, 5 (01) : 139 - 147